While there is evidence for the potential of enhancing chemotherapy efficacy through ADCY1 modulation in breast cancer [58], and a correlation has been established between overexpressed GNAO1 and poor prognosis in gastric cancer [59], there is a conspicuous lack of studies focusing on the role of these genes in HER2-positive breast cancer drug resistance. The gene discussed is ADCY1; the disease is gastric cancer.